EGFR Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

2019-03-31
Price :
Published : Mar-2019
No. of Pages : 0

EGFR Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Summary

EGFR Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

Globally, lung cancer is the second most common cancer in men and the third most common cancer in women. There are two main types of lung cancer; small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC accounting for approximately 80-90% of all lung cancer cases. The 5-year survival rate for patients with stage IV disease is less than 5% as majority of patients present with the advanced or metastatic disease at diagnosis. EGFR is a member of the receptor tyrosine kinase family and a major factor in regulating cellular proliferation, invasion, metastasis, angiogenesis, and inhibition of apoptosis. EGFR is one of the most routinely tested biomarkers in NSCLC.

EGFR mutation assays have evolved over the past decade. With numerous detection methods currently in clinical use, the consensus is that an ideal assay should be sensitive, effectively covering all clinically relevant targets with use of limited samples, and cost efficient. Most EGFR mutations found in adenocarcinoma are located in the tyrosine kinase domain. The most frequently encountered mutations are in-frame deletions in exon 19 (around 45%) and a point mutation in exon 21 (L858R), which together account for over 85% of described mutations. These mutations strongly correlate with NSCLC patients responding to EGFR therapies such as the tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib, afatinib, and icotinib.

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the Market Model

Currently marketed EGFR Tests and evolving competitive landscape –
– Insightful review of the key industry trends.
– Annualized total EGFR Tests market revenue by segment and market outlooks from 2015-2028.
– Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights –
– Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
– SWOT analysis for the market.
– Competitive dynamics insights and trends provided for the overall market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
– Country specific overview of the healthcare system.
– Country specific reimbursement policies.
– Country specific med-tech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for –
– CMO executives who must have deep understanding of the EGFR Tests marketplace to make strategic planning and investment decisions.
– Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
– Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to buy

The model will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving EGFR Tests market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the EGFR Tests market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track device sales in the global and country-specific EGFR Tests market from 2015-2028.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Filed in: In Vitro Diagnostic, Medical Device
Publisher : GlobalData
More Reports
Title Price Buy Now

Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028

Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028 Summary Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care. Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for new therapies that can reduce the great treatment burden associated with intravenous administration, the frequency of prophylactic infusions, and the risk of developing neutralizing a......
$10995

Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Human Immunodeficiency Virus (HIV) has become one of the world's most serious health issues affecting approximately 36.9 million people. The epidemiology of HIV infections varies from one geographical region to another. Sources indicate that in many countries, incidence rates for HIV have stabilized due to the campaigns that provide condoms, pre-exposure prophylaxis, sterile needles, syringes, antiretroviral therapy (ART), and prevention of mother-to-child transmission interv......
$7500

Chlamydia Trachomatis Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Chlamydia Trachomatis Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary Chlamydia Trachomatis Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia trachomatis. Patient access to Chlamydia screening, and thus the number of reported cases, varies substantially between countries. In some countries annual screening is recommended for specific patient groups deemed to be at higher risk of contracting the disease, such as sexually active females younger than 25 years. Additionally, screening of pregnant women for Chlamydia Trachomatis infections is currently recomme......
$7500

Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Cervical cancer screening has traditionally been based on cervical cytology. In recent years however, many countries have incorporated Human Papilloma Virus (HPV) tests into their cervical cancer and pre-cancer screening programs. Cytology based screening programs require a well-established healthcare infrastructure for processing and interpretation of samples. It is hoped that HPV screening methods may enable better prevention of these disease, these devices are also highly sensitive an......
$7500

Cytomegalovirus  (CMV) Tests (In Vitro Diagnostics) РGlobal Market Analysis and Forecast Model

"Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Cytomegalovirus (CMV) represents the most common congenital, viral infection in the developed world and awareness of this disease is increasing. Few countries have official guidelines in place for CMV screening but in general testing tends to be performed for sperm donations, immunocompromised cases, and pregnant women. Diagnosis of CMV infections is complex as symptoms are often non-specific and mimic mononucleosis or the flu. Approximately 21-25% of primary CMV infections are symptomatic ......
$7500

Hemostasis Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Hemostasis Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Hemostasis Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The increasing prevalence of surgical cases and rises in venous thromboembolism (VTE) incidence represent major driving factors for the hemostasis testing market. Prothrombin (PT) and Activated Prothrombin (aPTT) tests represent the most widely used Hemostasis tests. These devices are frequently utilized for coagulation testing prior to surgery while D-Dimer tests tend to be performed in VTE or suspected VTE cases. PT tests are also frequently used for monitoring of patients taking vitamin K antagonists such as warfarin......
$7500

Hematology Analyzers (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Hematology Analyzers (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Hematology Analyzers (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The market for automated Hematology Analyzers is increasing due to their reliability, advanced quality and fast testing mechanisms. The Hematology Analyzer market also benefits from rises in the prevalence of anaemia, increased incidence of blood related diseases and disorders, and the growing importance of blood cell counts in routine diagnostic procedures for patient treatment and monitoring. In developed and developing countries, hematology analyzers are installed in both hospital and reference laboratory set......
$7500

Colorectal Cancer Screening Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Colorectal Cancer Screening Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Colorectal Cancer Screening Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Aging populations and increasing disease awareness mean that colorectal cancer (CRC) screening has become a priority for many countries. A greater number of eligible inhabitants coupled with implementation of numerous national screening campaigns means that this in vitro diagnostics market is expected to grow across all regions during the forecast period. There are major disparities in the devices used for CRC screening around the world. Invasive colonoscopy procedures are the predomina......
$7500

Thyroid Function Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Thyroid Function Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Thyroid Function Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Thyroid Disease is the second most common endocrine disease after diabetes. The term "Thyroid Disease" encapsulates a number of conditions, including hyperthyroidism and hypothyroidism. Due to the fact that clinical symptoms of thyroid disease can vary substantially between patients and are often not specific, these conditions tend to be diagnosed using biochemical assays. The number and types of thyroid function tests (TFTs) performed per case depends on various factors such as the level of thyroid hormones ......
$7500

Prenatal Screening (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Prenatal Screening (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Prenatal Screening (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Prenatal Screening is now routinely used in developed countries for early detection of fetal abnormalities. Various biochemical analytes are measured during the first or second trimester including free-beta human chorionic gonadotropin (hCG), total hCG, pregnancy associated plasma protein-A (PAPP-A), Alpha-fetoprotein (AFP), unconjugated estriol (uE3), and Inhibin A. These markers are used to screen for Down syndrome (Trisomy 21) as well as Edwards syndrome (Trisomy 18) and ectopic pregnancy. Additionally, maternal s......
$7500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy